ADVFN Logo ADVFN

No pudimos encontrar ningún resultado para:
Asegúrate de que la ortografía sea correcta o intenta ampliar tu búsqueda.

Tendencias Ahora

Listas Principales

Parece que no has iniciado sesión.
Haz clic en el botón de abajo para iniciar sesión y ver tu historial reciente.

Regístrate

¿Ya eres miembro? Iniciar sesión

Los Principales Corredores en Línea

Más Corredores en Línea

Datos
Noticias
Herramientas
Mercados
Descubrir

Hot Features

Follow Feed

Conéctese con traders e inversores en nuestra comunidad Follow Feed.

Flujo de Opciones

Explora datos de opciones completos y utiliza filtros avanzados con Options Flow.

Monitor

Organiza y monitorea tu lista de seguimiento de acciones y activos con Monitor.
Iniciar Sesión Premium IconPremium Help Menu
S&P 500
6,049.24
0.88%
Dow Jones
44,025.81
1.24%
US Dollar vs MXN
20.64028
-0.12%
Brent Oil
78.415
-0.43%
Bitcoin
104,916.93
-1.18%
Pepperstone
Advertisement
Registration Strip Icon for alerts Regístrate para obtener alertas en tiempo real, cartera personalizada y movimientos del mercado.
Regístrate
  1. Inicio
  2. Invertir
  3. Acciones
  4. Estados Unidos
  5. NASDAQ

  6. Celyad Oncology SA (CYAD) Cotización

Celyad Oncology SA

Celyad Oncology SA (CYAD)

Celyad Oncology SA
0.47
0.00
(0.00%)
Cerrado 22 Enero 3:00PM
Delayed by 15 minutes
0.00
0.00
(0.00%)
Fuera de horario: -
Delayed by 15 minutes

Discusiones en tiempo real e ideas comerciales: opere con confianza con nuestra poderosa plataforma.

Premium

Estadísticas y detalles clave

Último Precio
0.47
Postura de Compra
0.47
Postura de Venta
0.52
Volume Operado de la Acción
-
0.00 Rango del Día 0.00
0.00 Rango de 52 semanas 0.00
Capitalización de Mercado [m]
19.472M
Precio Anterior
0.47
Precio de Apertura
-
Hora
Última hora de negociación
Volumen financiero
-
Precio Promedio Ponderado
-
Volumen promedio (3 m)
-
Acciones en circulación
41,429,000
Rendimiento del Dividendo
-
Ratio Precio/Utilidad
-2.60
Beneficio por acción (BPA)
-0.2
turnover
102k
Beneficio neto
-8.45M

Acerca de Celyad Oncology SA

Celyad Oncology is a biopharmaceutical company, specialized in cell therapy. It develops technologies and treatments to treat severe diseases with poor prognosis. The company focuses on Immuno Oncology, Cardiology, and Medical devices. Its main product candidates include CAR-T and C-Cure. The firm h... Celyad Oncology is a biopharmaceutical company, specialized in cell therapy. It develops technologies and treatments to treat severe diseases with poor prognosis. The company focuses on Immuno Oncology, Cardiology, and Medical devices. Its main product candidates include CAR-T and C-Cure. The firm has CYAD-01 and CYAD-02 programs in the pipeline. The company owns trademarks and service marks including CELYAD, C-CATH, C_CURE, CATH and C-CATHez and CARDIO 3 BIOSCIENCES. The firm has Cardiology and Immuno-oncology operating segments. Mostrar más

Sector
Pharmaceutical Preparations
Industria
Pharmaceutical Preparations
Sitio web
www.celyad.com
Sede
Mont-saint-guibert, Walloon Brabant, Bel
Fundado
-

CYAD Últimas noticias

Más noticias

Celyad Oncology annonce la nomination de Matt Kane au poste de CEO

Regulatory News: Celyad Oncology SA (Euronext & Nasdaq : CYAD) (la « Société » ou « Celyad ») est heureuse d’annoncer la nomination de Matt Kane au poste de Directeur Général (Chief...

16 Septiembre 2024
Business Wire

Celyad Oncology publie ses résultats financiers pour le premier semestre 2024 ainsi que les récents évènements marquants de son activité

La Société continue de renforcer sa propriété intellectuelle et d’explorer les options pour la monétiser Les deux principales plateformes de recherche et développement de la Société ont fourni...

13 Septiembre 2024
Business Wire

Celyad Oncology Reports Full Year 2023 Financial Results and Recent Business Highlights

Regulatory News: Celyad Oncology (Brussels:CYAD) (Paris:CYAD) (NASDAQ:CYAD) (the “Company”), today announces its financial results for the fiscal year 2023 ended December 31, 2023, and provides a...

04 Abril 2024
Business Wire

Celyad Oncology Announces Intention to Terminate SEC Reporting Obligations

Regulatory News: Celyad Oncology SA (Euronext: CYAD) (“Celyad Oncology” or the “Company”) announces that it will voluntarily file a Form 15F with the United States Securities and Exchange...

08 Febrero 2024
Business Wire

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

17 Enero 2024
Edgar (US Regulatory)

Celyad Oncology Provides Fourth Quarter 2023 Business Update and 2024 Outlook

Three main pillars to unlock the potential of proprietary technology platforms and intellectual property: A proprietary non-gene editing technology platform based on multiplexing of short hairpin...

16 Enero 2024
Business Wire
Período †Variación(Ptos)Variación %AperturaPrecio MáximoPrecio MínimoAvg. Vol. diarioPrecio Promedio Ponderado
10000000DR
40000000DR
120000000DR
260000000DR
520000000DR
1560000000DR
2600000000DR

CYAD - Preguntas Frecuentes

¿Cuál es el precio actual de las acciones de Celyad Oncology?
El precio actual de las acciones de Celyad Oncology es US$ 0.47
¿Cuántas acciones de Celyad Oncology están en circulación?
Celyad Oncology tiene 41,429,000 acciones en circulación
¿Cuál es la capitalización de mercado de Celyad Oncology?
La capitalización de mercado de Celyad Oncology es USD 19.47M
¿Cuál es el rango de negociación de 1 año para el precio de las acciones de Celyad Oncology?
Celyad Oncology ha negociado en un rango de US$ 0.00 a US$ 0.00 durante el último año
¿Cuál es el ratio PE (precio/beneficio) de Celyad Oncology?
El ratio precio/beneficio de Celyad Oncology es -2.6
¿Cuál es el ratio de efectivo a ventas de Celyad Oncology?
El ratio de efectivo a ventas de Celyad Oncology es 212
¿Cuál es la moneda de reporte de Celyad Oncology?
Celyad Oncology presenta sus resultados financieros en EUR
¿Cuál es el último ingresos anual de Celyad Oncology?
El último ingresos anual de Celyad Oncology es EUR 102k
¿Cuál es el último beneficio anual de Celyad Oncology?
El último beneficio anual de Celyad Oncology es EUR -8.45M
¿Cuál es la dirección registrada de Celyad Oncology?
La dirección registrada de Celyad Oncology es AXIS BUSINESS PARK, RUE ANDRE DUMONT 9, MONT-SAINT-GUIBERT, WALLOON BRABANT, 1435
¿Cuál es la dirección del sitio web de Celyad Oncology?
La dirección del sitio web de Celyad Oncology es www.celyad.com
¿En qué sector industrial opera Celyad Oncology?
Celyad Oncology opera en el sector PHARMACEUTICAL PREPARATIONS

Movimientos

Ver todo
  • Volumen
  • % Mayores Alzas
  • % Mayores Bajas
SímboloPrecioVol.
AALAmerican Airlines Group Inc
US$ 18.64
(0.00%)
0
AAGRAfrican Agriculture Holdings Inc
US$ 0.1326
(0.00%)
0
AADRAdvisorShares Dorsey Wright ADR ETF
US$ 74.3208
(0.00%)
0
AADIAadi Bioscience Inc
US$ 3.02
(0.00%)
0
AACGATA Creativity Global
US$ 0.94
(0.00%)
0
AALAmerican Airlines Group Inc
US$ 18.64
(0.00%)
0
AAGRAfrican Agriculture Holdings Inc
US$ 0.1326
(0.00%)
0
AADRAdvisorShares Dorsey Wright ADR ETF
US$ 74.3208
(0.00%)
0
AADIAadi Bioscience Inc
US$ 3.02
(0.00%)
0
AACGATA Creativity Global
US$ 0.94
(0.00%)
0
AALAmerican Airlines Group Inc
US$ 18.64
(0.00%)
0
AAGRAfrican Agriculture Holdings Inc
US$ 0.1326
(0.00%)
0
AADRAdvisorShares Dorsey Wright ADR ETF
US$ 74.3208
(0.00%)
0
AADIAadi Bioscience Inc
US$ 3.02
(0.00%)
0
AACGATA Creativity Global
US$ 0.94
(0.00%)
0

Discusión

Ver feed completo
wagner wagner 9 minutos hace
Look what they do...
https://criticalmetalscorp.gcs-web.com/news-releases/news-release-details/critical-metals-corp-announces-commencement-bitcoin-treasury


NB
AlwaysOptimistic AlwaysOptimistic 11 minutos hace
You’ve got a point. Curious why it was more important to be overseas coinciding with the inaugural. I’m no expert on the matter but it potentially gives the appearance of being a political decision. JMO
IONQ
AlwaysOptimistic AlwaysOptimistic 11 minutos hace
You’ve got a point. Curious why it was more important to be overseas coinciding with the inaugural. Seems political. JMO
IONQ
lovethatgreen lovethatgreen 12 minutos hace
Ok bud I appreciate you taking the time . I'm trying to find something solid it ain't easy
RITE
elks elks 12 minutos hace
He he. Lfg humbll
HMBL
DruidOracle55 DruidOracle55 16 minutos hace
They sold them to Warren Buffett and re-balanced their portfolio thereby making electro-magnetic acquisitions
AXXA
elks elks 19 minutos hace
Tic toc. Happy birthday George. Lfg.
GVSI
Angelmin Angelmin 20 minutos hace
Hi, Fully,
Me too, hope my first impression is wrong and we get what we want quickly.
FNMA
mascale mascale 21 minutos hace
Now personally waterchaser-poster acknowledged is the only Miro-connected insider information about a Miro sub-contractor with staff. No other poster alleges any comparable capability. The waterchaser first-name, pseudo-name, Miro former direct subcontractor participation is posted.
HIRU
Angelmin Angelmin 25 minutos hace
Hope you are right Rick,
 Maybe I become impatient and no longer trust politicians after following this for too long.
FNMA
thistraderknowsall thistraderknowsall 28 minutos hace
#1 MOMO CRYPTO BREAKOUT. VTHO!

Monday's national event bodes well for VTHO due to latest developments.. puts VTHO on track to $1 !!
Congrats!!

UP It goes !!we rich!!
Guido2 Guido2 34 minutos hace
Good DD. Keep it up.
FNMA
Fiberrevo9 Fiberrevo9 45 minutos hace
Kraig is number one on breakout boards on ihub...........WE HAVE THE ATTENTION!!!!!!
Might get the best performing stock in 2025.......Financing for expansion secured, a product that no one else in the world has, more positive than ever before......
KBLB
benyam benyam 53 minutos hace
$UMAV https://www.reddit.com/r/pennystocks/comments/1i71s0f/umav_the_earliest_investment_in_a_potential_drone/
UMAV
Flexplate Flexplate 1 hora hace
https://investingnews.com/north-bay-resources-acquires-70-interest-in-the-bishop-gold-mill-inyo-county-california/
For those that don't know, this means maximizing profits. $NBRI has been fine tuning the Bishop Gold Mill with ore shipped in from the Fran mine. Now that the fine tuning is comp
NBRI
Tahoe2468 Tahoe2468 1 hora hace

Oh I know that it is totally wrong but just wanted to see if someone could relay that to them hint hint 👍 I'm excited for updates!!!!! I found it on Charles Schwab app I
KRTL
fuagf fuagf 1 hora hace
Continued: Birthright citizenship EO jeopardizes insurance coverage

One new executive order .. https://www.whitehouse.gov/presidential-actions/2025/01/protecting-the-meaning-and-value-of-american-citizenship/ .. would upend birthright citizenship in the country under an argument that
Seminole Red Seminole Red 1 hora hace
lololol
PENNY PIRATE PENNY PIRATE 1 hora hace
alidare ... Hedge Funds Need Time to Cover Crime, Bottom Line IMHO! Naked Shorting is Illegal, they don't want to be Transparent, Question is, What do they need 6 months to do? Hide Crime! I say Raid the Offices, Freeze Accounts/Halt Trading Until Corrected and Confiscate what is Needed to Investiga
AABB
DruidOracle55 DruidOracle55 1 hora hace
They also have hotel on planet Bentar .
AXXA
DTGoody DTGoody 1 hora hace
Well maybe he invested in Bitcoin since 2017? LOL :) Interesting find for sure! It's nice having that pacer account.

I guess we will have to just wait and see where this is trading at in two years from now.

In the meantime, it's nice seeing the stock move back up in t
WPFH
Nebuchadnezzar Nebuchadnezzar 1 hora hace
2 separate REG D filings with SEC


SEC Filings

Form Type

D 01/13/2025
D 01/13/2025

15-12G 02/16/2018
SC 13G/A01/11/2018
SC 13G 04/25/2017
NT 10-K 03/31/2015
10-Q 03/31/2015
8-K
RITE
Zilidium Zilidium 1 hora hace
S-1 Does the forecast call for pain...

Pros: If PHIO demonstrates strong progress in its clinical trials, communicates a clear and effective use of proceeds, and generates positive clinical and financial milestones, the additional 5.9 million shares is a reasonable trade-off for long-
PHIO

Su Consulta Reciente

NASDAQ
CYAD
Celyad Oncology
BIT
S28678
Societe Generale Effekten
BIT
UC45ZC
Unicredit Bank
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

México
Empresa
Negocios
Popular
Obtener la aplicación
App Store
Google Play

Soporte: (55) 4170 8128 | soporte@advfn.mx

Al acceder a los servicios disponibles de ADVFN usted acepta quedar sujerto a los Términos y Condiciones

© 2025 ADVFN PLC - Todos los derechos reservados